Center for Translational & Policy Research on Personalized Medicine

Global Economics and Evaluation of Clinical Genomics Sequencing Working Group

Overview

The Global Economics and Evaluation of Clinical Genomics Sequencing Working Group (GEECS) is made up of an esteemed group of health economists and policy researchers from major institutions across the globe who have been at the forefront of the incorporation of genomics into clinical care. The working group is chaired by Kathryn A. Phillips, PhD, Director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) at UCSF.

Work

GEECS published a special theme section of the September 2018 issue of Value in Health specifically focuses on assessing the value of NGS-based clinical testing. This series of expert articles address challenges in assessing the value of NGS by not only highlighting them but by suggesting innovative solutions to move the value assessment process forward for precision medicine. The papers incorporate a wide range of perspectives and topics and use both systematic reviews and case studies – but they all focus on the overarching issue of proposing new methodologies to assess the value of NGS-based technologies in clinical care. The proposals included are not intended only for health economic researchers, but also to other stakeholders including health technology assessment organizations, payers, clinical researchers, and the biotechnology and pharmaceutical industries.

GEECS is continuing its work on measuring the value of NGS. The focus now is on methods for moving evaluation of precision medicine into practice. This work leverages and continues our two previous themed sections in Value in Health as well as a related theme issue in Health Affairs. This previous work identified evaluation challenges (particularly focusing on economic evaluation), potential solutions, and the impact of the changing context within which NGS tests are evaluated and covered by payers. In this new set of papers, we move beyond the identification of challenges to address how these challenges can be overcome so that we can move evaluation into practice and policy.

Group Members

James Buchanan, DPhil, University of Oxford, Oxford, United Kingdom
Kurt Christensen, PhD, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
Patricia Deverka, MD, MS, American Institutes for Research, Chapel Hill, NC, USA
Deborah Marshall, PhD, University of Calgary, Calgary, Alberta, Canada
Kathryn A. Phillips, PhD, University of California San Francisco, San Francisco, CA, USA
Dean Regier, PhD, University of British Columbia, Vancouver, British Columbia, Canada
Sarah Wordsworth, PhD, University of Oxford, Oxford, United Kingdom

TRANSPERS Center, UCSF | 3333 California Street #415, Box 0613, San Francisco, CA 94143
T: 415.502.4025 | transpersinfo@ucsf.edu | https://pharm.ucsf.edu/transpers

Center for Translational & Policy Research on Personalized Medicine

Publications

Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042.

Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using 'big' data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053.

Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of Health and Non-health Benefits from Next Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047.

Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. 2018; 21(9):1054-1061.

Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062-1068.

Phillips KA. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017 Jan;20(1):30-31

K.A. Phillips, M.P. Douglas, J.R. Trosman, et al."What goes around comes around": lessons learned from economic evaluations of personalized medicine applied to digital medicine. Value Health, 20 (2017), pp. 32-38

D.A. Marshall, J.M. Gonzalez, K.V. MacDonald, et al.Estimating preferences for complex health technologies: lessons learned and implications for personalized medicine. Value Health, 20 (2017), pp. 17-24

J.R. Trosman, C.B. Weldon, M.P. Douglas, et al.Decision making on medical innovations in a changing health care environment: insights from accountable care organizations and payers on personalized medicine and other technologies. Value Health, 20 (2017), pp. 25-31

M.B. Rosenman, B. Decker, K.D. Levy, et al.Lessons learned when introducing pharmacogenomic panel testing into clinical practice. Value Health, 20 (2017), pp. 39-44